Chronic pain and medical cannabis: Narrative review and practice considerations in persons living with HIV

被引:2
|
作者
Mills, Alex R. [1 ]
Nichols, Molly A. [2 ]
Davenport, Elizabeth [3 ]
机构
[1] Univ Mississippi, Sch Pharm, 2500 N State St, Jackson, MS 39216 USA
[2] Purdue Univ, Coll Pharm, Indianapolis, IN USA
[3] Spectrum Hlth Lakeland, St Joseph, MI USA
关键词
cannabidiol; cannabis; human immunodeficiency virus; opioids; pain; policy; SENSORY NEUROPATHY; DOUBLE-BLIND; PREVALENCE; ADHERENCE; MANAGEMENT; SYMPTOMS; OPIOIDS; ADULTS; ABUSE; CARE;
D O I
10.1002/jac5.1584
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Globally, 38 million persons live with human immunodeficiency virus (HIV) (PLWH), and a significant portion live with chronic pain. While not yet fully characterized, preliminary data suggest 40%-83% of PLWH experience chronic pain, and many report undertreatment. A growing body of literature suggests undertreatment of chronic pain in PLWH leads to adverse clinical outcomes, such as poor retention in HIV care, suboptimal adherence to antiretroviral therapy, and increased use of intravenous drug use (eg, heroin). Chronic pain experienced by PLWH ranges from neuropathic to musculoskeletal with different etiologies and treatment modalities for each. Although opioids have been used to achieve analgesia in PLWH, there is growing interest in alternative pain therapies. Recently, medical cannabis (delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]) products have been of high interest. Anecdotal evidence exists for medical cannabis and pain relief; however, robust clinical trial data are limited due to scheduling restrictions within the United States. The purposes of this narrative review are to summarize key literature for pain in PLWH and medical cannabis, discuss pertinent dosage forms and dosing schedules, and summarize safety and efficacy considerations for PLWH. Finally, the authors provide recommendations on cannabis rescheduling and pharmacists' and healthcare providers' roles in its prescribing and indication. Medical cannabis and pharmaceutical preparations containing both THC and CBD are a viable alternatives to opioid analgesics in the treatment of neuropathic pain in PLWH. The risks of misuse and cannabis use disorder warrant careful consideration, yet the benefits of effective analgesia associated with cannabis may outweigh these risks. Cannabis rescheduling and subsequent expansions in pain management research are warranted, particularly for CBD-predominant and CBD-isolate medical cannabis products.
引用
收藏
页码:342 / 353
页数:12
相关论文
共 50 条
  • [41] Spinal Cord Stimulation for Chronic Pain Syndromes: A Review of Considerations in Practice Management
    Karri, Jay
    Joshi, Mihir
    Polson, George
    Tang, Tuan
    Lee, Maxwell
    Orhurhu, Vwaire
    Deer, Timothy
    Abd-Elsayed, Alaa
    PAIN PHYSICIAN, 2020, 23 (06) : 599 - 616
  • [42] Intrathecal Drug Delivery for Chronic Pain Syndromes: A Review of Considerations in Practice Management
    Abd-Elsayed, Alaa
    Karri, Jay
    Michael, Ashley
    Bryce, David
    Sun, Jennifer
    Lee, Maxwell
    Orhurhu, Vwaire
    Deer, Timothy
    PAIN PHYSICIAN, 2020, 23 (06) : E591 - E617
  • [43] Medical cannabis for chronic pain: can it make a difference in pain management?
    Mari Kannan Maharajan
    Yu Jing Yong
    Hong Yang Yip
    Sze Shee Woon
    Kar Mon Yeap
    Khai Yeng Yap
    Shuen Chi Yip
    Kai Xian Yap
    Journal of Anesthesia, 2020, 34 : 95 - 103
  • [44] Medical cannabis for chronic pain: can it make a difference in pain management?
    Maharajan, Mari Kannan
    Yong, Yu Jing
    Yip, Hong Yang
    Woon, Sze Shee
    Yeap, Kar Mon
    Yap, Khai Yeng
    Yip, Shuen Chi
    Yap, Kai Xian
    JOURNAL OF ANESTHESIA, 2020, 34 (01) : 95 - 103
  • [45] Common differential diagnosis of low back pain in contemporary medical practice: a narrative review
    Ferdinandov, Dilyan
    Yankov, Dimo
    Trandzhiev, Martin
    FRONTIERS IN MEDICINE, 2024, 11
  • [46] Progression of cannabis withdrawal symptoms in people using medical cannabis for chronic pain
    Coughlin, Lara N.
    Ilgen, Mark A.
    Jannausch, Mary
    Walton, Maureen A.
    Bohnert, Kipling M.
    ADDICTION, 2021, 116 (08) : 2067 - 2075
  • [47] Driving under the influence of cannabis among medical cannabis patients with chronic pain
    Bonar, Erin E.
    Cranford, James A.
    Arterberry, Brooke J.
    Walton, Maureen A.
    Bohnert, Kipling M.
    Ilgen, Mark A.
    DRUG AND ALCOHOL DEPENDENCE, 2019, 195 : 193 - 197
  • [48] Healthcare professionals' perspectives on the use of medicinal cannabis to manage chronic pain: A systematic search and narrative review
    Cheng, Katherine Y. C.
    Harnett, Joanna E.
    Davis, Sharon R.
    Eassey, Daniela
    Law, Susan
    Smith, Lorraine
    PAIN PRACTICE, 2022, 22 (08) : 718 - 732
  • [49] Enhanced facilitation and diminished inhibition characterizes the pronociceptive endogenous pain modulatory balance of persons living with HIV and chronic pain
    Michael A. Owens
    Romy Parker
    Rachael L. Rainey
    Cesar E. Gonzalez
    Dyan M. White
    Anooshah E. Ata
    Jennifer I. Okunbor
    Sonya L. Heath
    Jessica S. Merlin
    Burel R. Goodin
    Journal of NeuroVirology, 2019, 25 : 57 - 71
  • [50] Enhanced facilitation and diminished inhibition characterizes the pronociceptive endogenous pain modulatory balance of persons living with HIV and chronic pain
    Owens, Michael A.
    Parker, Romy
    Rainey, Rachael L.
    Gonzalez, Cesar E.
    White, Dyan M.
    Ata, Anooshah E.
    Okunbor, Jennifer I.
    Heath, Sonya L.
    Merlin, Jessica S.
    Goodin, Burel R.
    JOURNAL OF NEUROVIROLOGY, 2019, 25 (01) : 57 - 71